Kolexia
Giacchetti Sylvie Oncologie médicale
Giacchetti Sylvie
Oncologie médicale
Hôpital Saint-Louis
Paris, France
155 Activités
26 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs colorectales Récidive tumorale locale Tumeurs du sein triple-négatives Carcinomes Tumeurs du foie Cancers du sein inflammatoires Aménorrhée

Collaborateurs

Voir plus
Espie Marc
Espie Marc
Hôpital Saint-Louis, Paris, France
Cuvier Caroline
Cuvier Caroline
Hôpital Saint-Louis, Paris, France
Chancerelle De Roquancourt Anne
Chancerelle De Roquancourt Anne
Hôpital Saint-Louis, Paris, France
Hamy-Petit Anne-Sophie
Hamy-Petit Anne-Sophie
Institut Curie, Saint-Cloud, France

Industries

Voir plus
Lilly
17 collaboration(s)
Dernière en 2023
Novartis
13 collaboration(s)
Dernière en 2023
AstraZeneca
10 collaboration(s)
Dernière en 2023
Eisai
5 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   01 février 2024
Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE): Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting
Essai Clinique (Institut Curie)   29 janvier 2024
Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.
JAMA network open   01 novembre 2023
Vinorelbine thiotepa in metastatic breast cancer: a large real-life retrospective study.
Acta oncologica (Stockholm, Sweden)   26 septembre 2023
CANTO: A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Cancer - Breast and Lung.
Essai Clinique (Unicancer)   20 avril 2023
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy: Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy
Essai Clinique (Unicancer)   28 février 2023
Giacchetti Discusses the Convergence of Chronobiology and ... - OncLive
OncLive   16 janvier 2023
Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network).
Breast (Edinburgh, Scotland)   31 décembre 2022
1551O Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Cáncer de mama metastásico
EMC - Ginecología-Obstetricia   01 juillet 2022